Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%
Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.
Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer
Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment
Relay Therapeutics Advances Towards Pivotal Trial with Promising Breast Cancer Data, Setting Stage for Competition with AstraZeneca’s Truqap
Relay Therapeutics, RLY-2608, Breast Cancer, PI3Kα Mutations, Pivotal Trial, AstraZeneca, Truqap
GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half
GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation
Zealand Pharma’s GLP-1/GLP-2 Receptor Dual Agonist Shows Promising Weight Loss in Phase 1b Trial
Zealand Pharma, GLP-1/GLP-2 receptor dual agonist, dapiglutide, obesity, weight loss, Phase 1b trial
Key Democrat to Oppose Biosecure Act, Citing Concerns Over Legislation’s Design and Impact on U.S.-China Biotech Relations
Biosecure Act, U.S.-China relations, biotech restrictions, national security, WuXi Biologics, BGI, Congressional opposition
FDA Grants Full Approval to Travere’s Filspari for IgA Nephropathy Treatment
Filspari, IgA Nephropathy, FDA Approval, Travere Therapeutics, Kidney Disease Treatment
Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment
Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies
GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results
GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.
Psyence Biomed to Acquire Clairvoyant Therapeutics, Expanding Psilocybin-Based Therapeutic Pipeline
Psilocybin, Psyence Biomed, Clairvoyant Therapeutics, Acquisition, Alcohol Use Disorder (AUD), Clinical Trials, Psychedelic Therapeutics